Details of the Drug-Related molecule(s) Expression Atlas
General Information of Drug (ID: DM973N4)
| Drug Name | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms | 
													 
								VIDUPIPRANT; 1169483-24-2; AMG 853; AMG-853; UNII-61OTZ32XNC; 61OTZ32XNC; 2-(4-(4-(tert-butylcarbamoyl)-2-(2-chloro-4-cyclopropylphenylsulfonamido)phenoxy)-5-chloro-2-fluorophenyl)acetic acid; CHEMBL1951575; AMG 853(AMG853;Vidupiprant); Benzeneacetic acid, 5-chloro-4-[2-[[(2-chloro-4-cyclopropylphenyl)sulfonyl]amino]-4-[[(1,1-dimethylethyl)amino]carbonyl]phenoxy]-2-fluoro-; Vidupiprant [USAN:INN]; AMG853;Vidupiprant; Vidupiprant (USAN/INN); AMG853; SCHEMBL4344221; GTPL10169; DTXSID40151606; BCP28132; ZINC43206238
								
							 
											 | 
				|||||||||||||||||||
| Indication | 
							
  | 
					|||||||||||||||||||
| Cross-matching ID | ||||||||||||||||||||
Molecule(s) Related to This Drug
![]() Drug Therapeutic Target (DTT)  | 
                
                    
  | 
            |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs
							
  | 
					|||||||||||||||||||||||||||||||||
| Molecule Expression Atlas in Normal Tissue of Major ADME-related organs | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue
| The Studied Disease | Asthma | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | CA23 | |||||||||||||||||||||||
							
  | 
					||||||||||||||||||||||||
| Molecular Expression Atlas between Disease Section and Healthy Individual Tissue | ||||||||||||||||||||||||

